Abstract
Cancer cells create a microenvironment that prevents tumor rejection by the host’s immune system. The activation of pattern recognition receptors (PRRs) can elicit an innate immune response and guide the adaptive immune response to overcome this. dsRNA analogs can trigger TLR3, RIG-I, MDA5, NLRP3 and several other PRRs to induce not only robust immune response against cancer but also programmed cell death. This review focuses on the signal pathways activated by dsRNA and examines examples of their clinical application in cancer treatment.
Keywords: Adjuvant, cancer vaccine, cross-presentation, cytokine, cytotoxic T lymphocyte, dendritic cell, double-stranded RNA, inflammasome, immune response, immunoediting, immunotherapy, melanoma differentiation-associated gene 5, nucleotide-binding domain and leucine-rich repeat containing gene family pyrin domain 3, polyadenylic-polyuridylic acid, polyinosinic-polycytidylic acid, poly (I:C12U), poly (ICLC), retinoic acid-inducible gene-I, T helper cell, toll-like receptor, tumor, tumor associated antigen.
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Analytical Chemistry
Current Computer-Aided Drug Design
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Related Books
test ebook
2-Deoxy-D-Glucose: Chemistry and Biology
Chiral Ionic Liquids: Applications in Chemistry and Technology
Anthocyanins: Pharmacology and Nutraceutical Importance
Therapeutic Insights into Herbal Medicine through the Use of Phytomolecules
Computer-Aided Drug Discovery Methods: A Brief Introduction
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Biochar - Solid Carbon for Sustainable Agriculture
DFT-Based Studies On Atomic Clusters
58